Evofem Biosciences (EVFM) Analyzed By H.C. Wainwright with $15 Target; Endologix Has 1.1 Sentiment

The stock decreased 7.48% or $0.56 during the last trading session, reaching $6.93. About 13,690 shares traded. Evofem Biosciences, Inc. (EVFM) has 0.00% since March 19, 2017 and is . It has underperformed by 16.70% the S&P500.

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company has market cap of $354.65 million. It offers minimally-invasive endovascular repair products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. It currently has negative earnings. The firm also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens.

The stock increased 4.43% or $0.18 during the last trading session, reaching $4.24. About 1.13M shares traded or 66.43% up from the average. Endologix, Inc. (ELGX) has declined 63.00% since March 19, 2017 and is downtrending. It has underperformed by 79.70% the S&P500.

Ratings analysis reveals 0 of Endologix’s analysts are positive. Out of 3 Wall Street analysts rating Endologix, 0 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. ELGX was included in 3 notes of analysts from September 6, 2016. On Tuesday, September 6 the stock rating was initiated by Leerink Swann with “Mkt Perform”. Canaccord Genuity downgraded the shares of ELGX in report on Thursday, November 17 to “Hold” rating. JP Morgan downgraded Endologix, Inc. (NASDAQ:ELGX) on Wednesday, November 16 to “Neutral” rating.

Mpm Asset Management Llc holds 2.44% of its portfolio in Endologix, Inc. for 1.12 million shares. Camber Capital Management Llc owns 8.00 million shares or 2.26% of their US portfolio. Moreover, Essex Woodlands Health Ventures Inc. has 2.03% invested in the company for 1.26 million shares. The California-based Redmile Group Llc has invested 1.44% in the stock. Senzar Asset Management Llc, a New York-based fund reported 901,541 shares.

Analysts await Endologix, Inc. (NASDAQ:ELGX) to report earnings on May, 3. They expect $-0.19 earnings per share, down 5.56% or $0.01 from last year’s $-0.18 per share. After $-0.08 actual earnings per share reported by Endologix, Inc. for the previous quarter, Wall Street now forecasts 137.50% negative EPS growth.

Evofem Biosciences, Inc. develops therapeutic solutions to meet sexual and reproductive health needs of women. The company has market cap of $123.06 million. The company's product includes, Amphora contraceptive for the prevention of pregnancy, antimicrobial drug product for the prevention of sexually transmitted infections, and antimicrobial drug product to prevent the reoccurrence of bacterial vaginosis. It currently has negative earnings. It also offers AMPOWER clinical research study, Chlamydia/Gonorrhea prevention clinical trial, and reduction in the recurrence of bacterial vaginosis clinical trial.